Arthropathy in thalassaemia patients receiving deferiprone
- 11 June 1994
- journal article
- Published by Elsevier BV in The Lancet
- Vol. 343 (8911), 1471-1472
- https://doi.org/10.1016/s0140-6736(94)92585-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trialBritish Journal of Haematology, 1992
- Efficacy and possible adverse effects of the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major [see comments]Blood, 1992
- Development of iron-chelating agents for clinical use [editorial; comment]Blood, 1992
- Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in cultureBlood, 1991
- Antinuclear antibodies in patients taking L1The Lancet, 1991
- Fatal systemic lupus erythematosus in patient taking oral iron chelator L1The Lancet, 1991
- Iron chelation in rheumatoid arthritis: clinical and laboratory evaluation.Annals Of The Rheumatic Diseases, 1990
- THE IMPORTANCE OF IRON IN RHEUMATOID DISEASEThe Lancet, 1981
- Thalassemic OsteoarthropathyAnnals of Internal Medicine, 1978